Paper41375007
Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations.
Salfi G and 14 others. Cancers (Basel), 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations. Papers, record 41375007. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41375007
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39521639 | Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216. | Eur Urol Oncol | 2025 | https://conductscience.org/library/papers/39521639 | PubMed |
| 2 | 20888271 | Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. | Urol Oncol | 2012 | https://conductscience.org/library/papers/20888271 | PubMed |
| 3 | 19399748 | Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. | Cancer | 2009 | https://conductscience.org/library/papers/19399748 | PubMed |
| 4 | 38688773 | EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. | Eur Urol | 2024 | https://conductscience.org/library/papers/38688773 | PubMed |
| 5 | 31843335 | Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study. | Eur Urol | 2020 | https://conductscience.org/library/papers/31843335 | PubMed |
| 6 | 10737287 | Clinical survival predictors in patients with advanced cancer. | Arch Intern Med | 2000 | https://conductscience.org/library/papers/10737287 | PubMed |
| 7 | 39279580 | Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/39279580 | PubMed |
| 8 | 30477464 | Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival? | BMC Cancer | 2018 | https://conductscience.org/library/papers/30477464 | PubMed |
| 9 | 33058693 | Machine Learning in Oncology: Methods, Applications, and Challenges. | JCO Clin Cancer Inform | 2020 | https://conductscience.org/library/papers/33058693 | PubMed |
| 10 | 29339044 | The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. | Clin Genitourin Cancer | 2018 | https://conductscience.org/library/papers/29339044 | PubMed |
| 11 | 17997442 | Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase. | J Urol | 2008 | https://conductscience.org/library/papers/17997442 | PubMed |
| 12 | 36682938 | Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis. | Eur Urol Oncol | 2023 | https://conductscience.org/library/papers/36682938 | PubMed |
| 13 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 14 | 33866442 | Cardiovascular Toxicities of Androgen Deprivation Therapy. | Curr Treat Options Oncol | 2021 | https://conductscience.org/library/papers/33866442 | PubMed |
| 15 | 29475737 | Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. | Eur Urol | 2018 | https://conductscience.org/library/papers/29475737 | PubMed |
| 16 | 39641119 | Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study. | Eur Urol Open Sci | 2025 | https://conductscience.org/library/papers/39641119 | PubMed |
| 17 | 28899723 | Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease. | Clin Genitourin Cancer | 2017 | https://conductscience.org/library/papers/28899723 | PubMed |
| 18 | 31150574 | Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31150574 | PubMed |
| 19 | 31092914 | A new era: artificial intelligence and machine learning in prostate cancer. | Nat Rev Urol | 2019 | https://conductscience.org/library/papers/31092914 | PubMed |
| 20 | 29261442 | Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. | J Clin Oncol | 2018 | https://conductscience.org/library/papers/29261442 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| NPEPPS | 9520 | PubTator's text mining | https://conductscience.org/library/genes/9520 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41375007
GET https://conductscience.org/api/papers/v1/41375007/references?page=2